Clearmind Medicine (CMND) reports successful intranasal MEAI feasibility study

(Neutral)

Form Type

6-K

Rhea-AI Filing Summary

Clearmind Medicine Inc. furnished a Form 6-K highlighting a successful formulation feasibility study for an intranasal version of its lead compound MEAI, initially targeted at alcohol use disorder. The work showed MEAI can be incorporated into a stable, fully soluble intranasal formulation, supporting continued development of this additional route of administration.

The first five paragraphs of the press release are also incorporated by reference into Clearmind’s existing Form F-3 and Form S-8 registration statements, making this R&D update part of those offerings’ disclosure record.

Key Figures

Patent families: 19 patent families Granted patents: 32 granted patents Form types incorporated: Form F-3 and Form S-8

3 metrics

Patent families 19 patent families Company intellectual property portfolio

Granted patents 32 granted patents Company intellectual property portfolio

Form types incorporated Form F-3 and Form S-8 Press release paragraphs incorporated by reference

Key Terms

Formulation feasibility study, Intranasal delivery, Alcohol use disorder (AUD), Neuroplastogen-derived therapeutics, +2 more

6 terms

Formulation feasibility study technical

"The studies demonstrated that MEAI can be successfully incorporated into the formulation"

Intranasal delivery technical

"evaluating intranasal delivery of its proprietary MEAI as a potential additional route of administration"

A method of giving a drug or vaccine through the nose using sprays, drops, or inhaled particles so the medicine is absorbed by nasal tissues and can enter the bloodstream or reach the brain more directly than an oral pill. Investors care because intranasal delivery can speed onset, avoid needles, lower manufacturing or distribution costs, and open new markets for treatments that are hard to administer by mouth or injection—factors that affect a product's commercial potential and regulatory path.

Alcohol use disorder (AUD) medical

"initially for the treatment of alcohol use disorder (AUD)"

A chronic medical condition in which a person repeatedly drinks alcohol in a way that they cannot control, continuing despite harm to their health, work or relationships; it ranges from risky drinking to severe dependence. Investors should care because AUD drives demand for treatments, public health spending, workplace productivity losses and regulatory attention—similar to how a persistent mechanical problem increases repair and operating costs, it creates long-term market and policy implications for healthcare, insurers and employers.

Neuroplastogen-derived therapeutics medical

"second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems"

Neuroplastogen-derived therapeutics are drugs or biological treatments developed from compounds that promote neuroplasticity — the brain’s ability to rewire and form new connections after injury or in response to learning. For investors, they matter because these therapies target underlying brain repair mechanisms rather than only masking symptoms, offering the potential for durable benefits in conditions like depression, stroke recovery, or neurodegeneration; if effective, they can create large, high-value markets similar to replacing a faulty bridge with a stronger one.

Registration Statements on Form F-3 regulatory

"incorporated by reference into the Registrant’s Registration Statements on Form F-3"

Form S-8 regulatory

"and Form S-8 (File No. 333-283695), filed with the Securities and Exchange Commission"

A Form S-8 is a U.S. Securities and Exchange Commission registration that lets a public company set aside shares for employee benefit plans and stock-based compensation. Think of it as opening a dedicated account that authorizes the company to issue or reserve stock for workers and directors; it matters to investors because it enables share dilution when those awards are granted or exercised and signals how management is compensated and incentivized.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 07/07/2026 - 04:02 PM Accepted by SEC EDGAR 07/07/2026 - 04:01 PM

FAQ

What did Clearmind Medicine (CMND) announce about its MEAI intranasal program?

Clearmind reported a successful formulation feasibility study for intranasal delivery of MEAI. The compound was formulated into a stable, fully soluble intranasal solution, supporting further development of this additional administration route for treating alcohol use disorder.

Why is Clearmind Medicine’s intranasal MEAI study important for alcohol use disorder (AUD)?

The study supports intranasal MEAI as a potential new treatment option for AUD. Clearmind aims to combine a novel therapeutic molecule with an advanced delivery platform to improve patient experience, convenience, and therapeutic performance in a condition with limited effective treatments.

How does this Form 6-K affect Clearmind Medicine’s existing registration statements?

The first five paragraphs of the press release are incorporated into Clearmind’s Form F-3 and Form S-8 registration statements. This means the intranasal MEAI feasibility results now form part of the company’s official disclosure for those previously filed securities offerings.

What is MEAI and how is Clearmind Medicine (CMND) developing it?

MEAI is Clearmind’s proprietary therapeutic candidate, a non-hallucinogenic, neuroplastogen-derived compound for addiction-related disorders including alcohol use disorder. The company is developing it across different delivery systems, now including an intranasal route supported by recent formulation feasibility results.

What stage of development is Clearmind Medicine’s intranasal MEAI program in now?

The program has completed formulation-feasibility work demonstrating MEAI can be stably formulated for intranasal use. These findings provide a basis for further formulation optimization and subsequent development activities, but do not yet represent late-stage clinical trial results or approval.

What intellectual property position does Clearmind Medicine report around its programs?

Clearmind states it has nineteen patent families with 32 granted patents. The company plans to seek additional patents on its compounds when appropriate and may acquire more intellectual property to strengthen its portfolio across therapeutic candidates and delivery approaches.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: July 2026

Commission file number: 001-41557

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is the Registrant’s press release issued on July 7, 2026, titled “Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI”.

The first five paragraphs of the press release attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File No. 333-275991, 333-270859, 333-273293, 333-290404, 333-293521 and 333-295455) and Form S-8 (File No. 333-283695), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit No.
99.1		Press release titled: “Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Clearmind Medicine, Inc.
	(Registrant)

Date: July 7, 2026	By:	/s/ Adi Zuloff-Shani
	Name:	Adi Zuloff-Shani
	Title:	Chief Executive Officer

Exhibit 99.1

Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI

Vancouver, Canada, July 07, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, such as addictions and weight-loss, announced continued progress in evaluating intranasal delivery of its proprietary MEAI (5-Methoxy-2-aminoindane) as a potential additional route of administration, initially for the treatment of alcohol use disorder (AUD).

The program is evaluating intranasal delivery of MEAI as a potential additional route of administration, with initial studies focused on assessing formulation feasibility and supporting the continued development of this delivery approach.

AUD remains a significant unmet medical need worldwide, affecting millions and placing a substantial burden on patients, families, and healthcare systems. Available treatment options are limited with limited efficacy and poor adherence, altogether, underscoring the need for novel therapeutic approaches. Clearmind’s intranasal MEAI program aims to address this unmet need by combining a novel therapeutic molecule with an advanced drug delivery platform designed to improve patient experience, convenience, and therapeutic performance.

MEAI is Clearmind’s lead proprietary therapeutic candidate and is being developed as a potential treatment for addiction-related disorders, including AUD. The molecule has demonstrated promising characteristics in preclinical and clinical studies and represents a novel approach for addressing compulsive alcohol consumption and other alcohol-related behaviors. The program is intended to evaluate whether intranasal administration can further enhance the therapeutic potential of MEAI by providing additional delivery routes that are efficient and user-friendly.

As part of its strategy to explore additional delivery systems for MEAI, Clearmind initiated formulation-feasibility studies to evaluate the compound’s suitability for intranasal administration. Initial work focused on evaluating MEAI’s compatibility with the formulation system and its suitability for intranasal administration. The studies demonstrated that MEAI can be successfully incorporated into the formulation, resulting in a stable and fully soluble solution. These findings provide a strong foundation for subsequent development activities and support the continued advancement of the program.

“This development program represents our ongoing efforts to maximize the therapeutic potential of MEAI,” said Dr. Adi Zuloff-Shani, CEO of Clearmind. “We believe that the successful formulation feasibility results support the potential of intranasal delivery of MEAI and provide a strong basis for further formulation optimization.”

About Clearmind Medicine Inc.

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

The Company’s intellectual portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND.”

For further information, visit: https://www.clearmindmedicine.com or contact:

Investor Relations

invest@clearmindmedicine.com

www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the timing and progress of its clinical studies, how Clearmind’s intranasal MEAI program aims to address the unmet need of limited treatment options for AUD by combining a novel therapeutic molecule with an advanced drug delivery platform designed to improve patient experience, convenience, and therapeutic performance, the expected benefits of the collaboration that is intended to evaluate whether intranasal administration can further enhance the therapeutic potential of MEAI by providing additional delivery routes that are efficient and user-friendly, its its strategy to explore additional delivery systems for MEAI, subsequent development activities and support the continued advancement of its MEAI program, its ongoing efforts to maximize the therapeutic potential of MEAI and its belief that the successful formulation feasibility results support the potential of intranasal delivery of MEAI and provide a strong basis for further formulation optimization.. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases

EX-99.1 PRESS RELEASE TITLED: "CLEARMIND REPORTS SUCCESSFUL FORMULATION FEASIBILITY STUD 12.4 KB